

**Press release March 31, 2022**

### **Infant Bacterial Therapeutics publishes Annual Report for 2021**

Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021.

The report is available on IBT's website [ibtherapeutics.com](http://ibtherapeutics.com) under the section "Investors & Media – Financial Reports" and is available in printed form for those that have requested. A copy can be requested by contacting IBT's office via [info@ibtherapeutics.com](mailto:info@ibtherapeutics.com).

#### ***About Infant Bacterial Therapeutics AB***

Infant Bacterial Therapeutics AB ("IBT") is a public company domiciled in Stockholm. The company's Class B shares are listed on Nasdaq Stockholm, Small-cap (IBT B).

Infant Bacterial Therapeutics AB (publ) ("IBT") is a pharmaceutical company with a product in clinical phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.

IBT is currently developing the drug candidate IBP-9414. The ambition for IBP-9414 is to become the world's first approved probiotic drug with the goal to prevent life threatening diseases in premature infants including NEC and sepsis by promoting sound stomach-and bowel development in premature infants. IBP-9414 contains the active compound *Lactobacillus reuteri*, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.

#### **For additional information please contact**

Staffan Strömberg, CEO  
Michael Owens, CFO  
Infant Bacterial Therapeutics AB Bryggargatan 10  
111 21 Stockholm  
Phone: +46 76 219 37 38

[info@ibtherapeutics.com](mailto:info@ibtherapeutics.com)

[www.ibtherapeutics.com](http://www.ibtherapeutics.com)

#### **Publication**

The information was submitted for publication, by the contact persons set out above, at 08:00 CET on March 31, 2022.